Celadon Pharmaceuticals PLC 140.9% potential upside indicated by Canaccord Genuity

Celadon Pharmaceuticals PLC with ticker (LON:CEL) now has a potential upside of 140.9% according to Canaccord Genuity.



Canaccord Genuity set a target price of 235 GBX for the company, which when compared to the Celadon Pharmaceuticals PLC share price of 98 GBX at opening today (20/10/2023) indicates a potential upside of 140.9%. Trading has ranged between 48 (52 week low) and 189 (52 week high) with an average of 28,813 shares exchanging hands daily. The market capitalisation at the time of writing is £64,343,863.

Celadon Pharmaceuticals Plc is a United Kingdom-based pharmaceutical company. The Company is engaged in research, cultivation, manufacturing and supply of cannabinoid-based medicines. The Company is focused on growing indoor hydroponic cannabis initially for the chronic pain market. It is also focused on improving the quality of life for chronic pain sufferers, as well as exploring the potential of cannabinoid-based medicines for other conditions, such as autism and multiple sclerosis. The Company’s facility comprises an indoor, closed-loop hydroponic system to ensure cannabis plants are cultivated under a highly specific climate, light and with irrigation control. The Company’s subsidiary, LVL Health is a medical cannabis clinic for chronic pain that owns a medicines and healthcare products regulatory agency (MHRA) conditionally approved cannabis trial using cannabis-based medicinal products to treat chronic pain in the United Kingdom.